Rockefeller Capital Management
NKTR icon

Rockefeller Capital Management’s Nektar Therapeutics NKTR Stock Holding History

Rockefeller Capital Management’s Portfolio NKTR Stock Details NKTR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$14K Buy
+200
New +$14.6K ﹤0.01% 3876
2023
Q1 		– Sell
-10
Closed – – 3209
2022
Q4 		$0 Hold
10
– – ﹤0.01% 4090
2022
Q3 		$0 Buy
+10
New +$595 ﹤0.01% 4214
2021
Q3 		– Sell
-27
Closed -$6K – 3797
2021
Q2 		$6K Hold
27
– – ﹤0.01% 2980
2021
Q1 		$8K Hold
27
– – ﹤0.01% 2695
2020
Q4 		$6K Sell
27
-15
-36% -$3.88K ﹤0.01% 2382
2020
Q3 		$10K Buy
42
+6
+17% +$1.89K ﹤0.01% 2017
2020
Q2 		$13K Sell
36
-8
-18% -$2.5K ﹤0.01% 1817
2020
Q1 		$12K Buy
44
+16
+57% +$4.95K ﹤0.01% 1688
2019
Q4 		$9K Buy
28
+1
+4% +$290 ﹤0.01% 1639
2019
Q3 		$7K Buy
+27
New +$9.9K ﹤0.01% 1533
2019
Q2 		– Sell
-15
Closed -$8K – 1863
2019
Q1 		$8K Buy
+15
New +$8.89K ﹤0.01% 1536

Other funds holding NKTR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $5.05B AUM 164.99% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Rockefeller Capital Management's NKTR Position: Q2 2026 in Review

Rockefeller Capital Management opened a new position in Nektar Therapeutics (NKTR) in Q2 2026: 200 shares worth $14K. The stake represents ﹤0.01% of the portfolio and ranks #3876 among its holdings. This is a return to the name: Rockefeller Capital Management previously reported a position in NKTR as recently as Q4 2022.

Rockefeller Capital Management first reported a position in NKTR in Q1 2019 and has held it in 12 quarters since. 239 funds tracked by Wall St. Rank hold NKTR as of Q2 2026.

  • Rockefeller Capital Management held 200 shares of Nektar Therapeutics worth $14K as of Q2 2026.
  • Nektar Therapeutics was a new Rockefeller Capital Management position in Q2 2026.
  • Nektar Therapeutics made up ﹤0.01% of Rockefeller Capital Management's portfolio in Q2 2026, its #3876 holding.
  • Rockefeller Capital Management first reported a position in Nektar Therapeutics in Q1 2019 and has held it in 12 quarters since.
  • 239 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q2 2026.

Based on Rockefeller Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.